Devi SenGupta

5.5k total citations · 1 hit paper
46 papers, 1.2k citations indexed

About

Devi SenGupta is a scholar working on Infectious Diseases, Virology and Immunology. According to data from OpenAlex, Devi SenGupta has authored 46 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 20 papers in Virology and 13 papers in Immunology. Recurrent topics in Devi SenGupta's work include HIV Research and Treatment (20 papers), HIV/AIDS drug development and treatment (13 papers) and HIV/AIDS Research and Interventions (8 papers). Devi SenGupta is often cited by papers focused on HIV Research and Treatment (20 papers), HIV/AIDS drug development and treatment (13 papers) and HIV/AIDS Research and Interventions (8 papers). Devi SenGupta collaborates with scholars based in United States, United Kingdom and Spain. Devi SenGupta's co-authors include Andrew Cheng, Douglas F. Nixon, Anton Pozniak, Joseph M. Custodio, Steven G. Deeks, Erin Quirk, Kirsten White, Jihad Slim, Edwin DeJesus and Paul E. Sax and has published in prestigious journals such as The Lancet, The Journal of Immunology and PLoS ONE.

In The Last Decade

Devi SenGupta

44 papers receiving 1.2k citations

Hit Papers

Coformulated bictegravir, emtricitabine, and tenofovir al... 2017 2026 2020 2023 2017 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
    2017 278 citations Paul E. Sax, Anton Pozniak et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Devi SenGupta United States 19 728 507 278 250 243 46 1.2k
Jose L. Matud United States 20 670 0.9× 1.0k 2.0× 162 0.6× 416 1.7× 155 0.6× 25 1.8k
Catherine Tamalet France 22 715 1.0× 813 1.6× 132 0.5× 345 1.4× 141 0.6× 49 1.3k
Alain Lafeuillade France 24 1.1k 1.5× 1.2k 2.3× 280 1.0× 368 1.5× 89 0.4× 89 1.7k
Birgit Schramm France 18 400 0.5× 570 1.1× 32 0.1× 175 0.7× 162 0.7× 38 1.1k
Randall Lanier United States 16 347 0.5× 467 0.9× 34 0.1× 452 1.8× 259 1.1× 31 814
Moraima Guadalupe United States 13 570 0.8× 1000 2.0× 234 0.8× 468 1.9× 264 1.1× 13 1.6k
Jacques Homsy United States 15 382 0.5× 645 1.3× 47 0.2× 270 1.1× 104 0.4× 20 962
Mounir Ait‐Khaled United Kingdom 21 1.2k 1.7× 991 2.0× 267 1.0× 486 1.9× 117 0.5× 54 1.5k
Michiko Koga Japan 17 400 0.5× 212 0.4× 86 0.3× 252 1.0× 209 0.9× 68 802
Shelly J. Krebs United States 20 416 0.6× 564 1.1× 258 0.9× 216 0.9× 216 0.9× 43 1.1k

Countries citing papers authored by Devi SenGupta

Since Specialization
Citations

This map shows the geographic impact of Devi SenGupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devi SenGupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devi SenGupta more than expected).

Fields of papers citing papers by Devi SenGupta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devi SenGupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devi SenGupta. The network helps show where Devi SenGupta may publish in the future.

Co-authorship network of co-authors of Devi SenGupta

This figure shows the co-authorship network connecting the top 25 collaborators of Devi SenGupta. A scholar is included among the top collaborators of Devi SenGupta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Devi SenGupta. Devi SenGupta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bailón, Lucía, José Ramón Arribas, Adrián Curran, et al.. (2025). Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._. Communications Medicine. 6(1). 11–11.
2.
Rappaport, Amy, Elena Bekerman, Brian Carr, et al.. (2025). Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist. The Journal of Immunology. 214(3). 489–501. 1 indexed citations
3.
Riddler, Sharon A., Constance A. Benson, Steven G. Deeks, et al.. (2024). A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod. Infectious Diseases and Therapy. 13(11). 2285–2299. 1 indexed citations
4.
Magombedze, Gesham, Elena Vendrame, Devi SenGupta, et al.. (2024). Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment Interruption. The Journal of Infectious Diseases. 231(2). e419–e428. 1 indexed citations
5.
Abdel‐Mohsen, Mohamed, Steven G. Deeks, Leila B. Giron, et al.. (2024). Circulating immune and plasma biomarkers of time to HIV rebound in HIV controllers treated with vesatolimod. Frontiers in Immunology. 15. 1405348–1405348. 2 indexed citations
6.
Llano, Anuska, Santiago Cedeño, Pep Coll, et al.. (2021). A placebo-controlled ati trial of HTI vaccines in early treated HIV infection. 29(1). 48–49. 5 indexed citations
7.
Lewin, Sharon R., Brian Doehle, Karine Dubé, et al.. (2020). Multi-stakeholder consensus on a target product profile for an HIV cure. The Lancet HIV. 8(1). e42–e50. 48 indexed citations
8.
Raposo, Rui André Saraiva, Margaret M. Lowe, Elisabeth Krow‐Lucal, et al.. (2017). Relative mRNA Expression Levels of Restriction Factors and Antiviral Genes in Fetal and Adult Human Monocytes and Monocyte-Derived Macrophages. Viral Immunology. 30(3). 142–148. 3 indexed citations
9.
10.
Sax, Paul E., Anton Pozniak, Marisa Montes, et al.. (2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet. 390(10107). 2073–2082. 278 indexed citations breakdown →
11.
Ribeiro, Susan Pereira, Jeffrey M. Milush, Edécio Cunha‐Neto, et al.. (2016). p16INK4a Expression and Immunologic Aging in Chronic HIV Infection. PLoS ONE. 11(11). e0166759–e0166759. 29 indexed citations
12.
13.
Paquin‐Proulx, Dominic, Christina B. Ching, Ivan Vujkovic-Cvijin, et al.. (2016). Bacteroides are associated with GALT iNKT cell function and reduction of microbial translocation in HIV-1 infection. Mucosal Immunology. 10(1). 69–78. 36 indexed citations
14.
Pozniak, Anton, José Ramón Arribas, Joseph Gathe, et al.. (2016). Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas). 12 indexed citations
15.
Pozniak, Anton, José Ramón Arribas, Joseph Gathe, et al.. (2015). Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 71(5). 530–537. 158 indexed citations
16.
Ormsby, Christopher E., Devi SenGupta, Ravi Tandon, et al.. (2012). Human Endogenous Retrovirus Expression Is Inversely Associated with Chronic Immune Activation in HIV-1 Infection. PLoS ONE. 7(8). e41021–e41021. 22 indexed citations
17.
Tandon, Ravi, Devi SenGupta, Vanessa A. York, et al.. (2012). Age-Related Expansion of Tim-3 Expressing T Cells in Vertically HIV-1 Infected Children. PLoS ONE. 7(9). e45733–e45733. 15 indexed citations
18.
SenGupta, Devi, Philip J. Norris, Todd J. Suscovich, et al.. (2004). Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II. The Journal of Immunology. 173(3). 1987–1993. 63 indexed citations
19.
SenGupta, Devi, et al.. (1984). Occurrence of Cysticercus bovis in slaughtered cattle and buffaloes in Calcutta and its public health significance.. Indian Journal of Animal Health. 23(2). 141–145. 3 indexed citations
20.
SenGupta, Devi, et al.. (1968). An outbreak of infective hepatitis within the campus of Calcutta Hospital.. The Indian Journal of Medical Research. 56(10). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jose L. Matud Breakdown of academic impact, for papers by Catherine Tamalet Breakdown of academic impact, for papers by Alain Lafeuillade Breakdown of academic impact, for papers by Birgit Schramm Breakdown of academic impact, for papers by Randall Lanier Breakdown of academic impact, for papers by Moraima Guadalupe Breakdown of academic impact, for papers by Jacques Homsy Breakdown of academic impact, for papers by Mounir Ait‐Khaled Breakdown of academic impact, for papers by Michiko Koga Breakdown of academic impact, for papers by Shelly J. Krebs
Rankless by CCL
2026